KTP 001

Drug Profile

KTP 001

Alternative Names: KTP-001; Recombinant human matrix metalloproteinase - Kaketsuken/Teijin

Latest Information Update: 02 Oct 2015

Price : $50

At a glance

  • Originator University of Yamanashi; Yokohama City Minato Red Cross Hospital
  • Developer Kaketsuken; Teijin Pharma
  • Class Matrix metalloproteinases; Recombinant proteins
  • Mechanism of Action Matrix-metalloproteinase-stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Intervertebral disc displacement

Most Recent Events

  • 17 Sep 2015 KTP 001 is still in phase I/II trials for Intervertebral disc displacement in USA
  • 01 Feb 2013 Teijin Pharma initiates enrolment in a phase I/II trial in Intervertebral disc displacement in USA (NCT01978912)
  • 29 Oct 2012 KTP 001 is available for licensing in World (excluding Japan) as of 29 Oct 2012. http://www.teijin-pharma.co.jp
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top